Literature DB >> 30470540

Neoadjuvant or adjuvant chemotherapy for non-small-cell lung cancer: Does the timing matter?

Yang Zhang1, Haiquan Chen2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30470540     DOI： 10.1016/j.jtcvs.2018.10.006

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN： 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  4 in total

Review 1.  Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer.

Authors:  Fabrizio Tabbò; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2019-11

2.  Vomiting Management and Effect Prediction after Early Chemotherapy of Lung Cancer with Diffusion-Weighted Imaging under Artificial Intelligence Algorithm and Comfort Care Intervention.

Authors:  Cailing Mei; Ling Zhang; Zhiying Zhang
Journal:  Comput Math Methods Med       Date:  2022-06-15       Impact factor: 2.809

3.  Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I-IIIA non-small cell lung cancer: a propensity-matched analysis.

Authors:  Junjie Xi; Yajing Du; Zhengyang Hu; Jiaqi Liang; Yunyi Bian; Zhencong Chen; Qihai Sui; Cheng Zhan; Ming Li; Weigang Guo
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 2.895

4.  Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?

Authors:  Timothée Olivier; Vinay Prasad
Journal:  Transl Oncol       Date:  2022-08-04       Impact factor: 4.803
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.